Table 1. Sequence analyses of different... | American Society of Hematology

Table 1.

Sequence analyses of different clinical stages in a patient with congenital neutropenia who developed acute myeloid leukemia

	CN			CN/AML		During chemotherapy June 1998	Complete remission July 1998	After BMT August 1999
Time point	Nov 1989^*	May 1994	April 1996	March 1998		During chemotherapy June 1998	Complete remission July 1998	After BMT August 1999
Sample material	BM gDNA	PB-PMC RNA	PB-MNC RNA	PB-PMC RNA	PB-MNC RNA	PB-PMC RNA	PB-PMC RNA	PB-PMC RNA
Total number of clones tested (100%)	25	27	26	32	28	26	25	28
No. of mutated clones
nt 2390 C → T^†	—	—	—	2 (6%)	—	—	—	—
nt 2414 C → T	—	3 (11%)	2 (8%)	1 (3%)	1 (4%)	—	—	—
nt 2363 G → A plus nt 2414 C → T	—	16 (59%)	7 (27%)	10 (31%)	12 (43%)	—	—	—
nt 2363 G → A	15 (60%)	3 (11%)	6 (23%)	5 (16%)	—	10 (38%)	11 (44%)	—
Wild-type sequence	10 (40%)	5 (19%)	11 (42%)	14 (44%)	15 (53%)	16 (62%)	14 (56%)	28 (100%)

	CN			CN/AML		During chemotherapy June 1998	Complete remission July 1998	After BMT August 1999
Time point	Nov 1989^*	May 1994	April 1996	March 1998		During chemotherapy June 1998	Complete remission July 1998	After BMT August 1999
Sample material	BM gDNA	PB-PMC RNA	PB-MNC RNA	PB-PMC RNA	PB-MNC RNA	PB-PMC RNA	PB-PMC RNA	PB-PMC RNA
Total number of clones tested (100%)	25	27	26	32	28	26	25	28
No. of mutated clones
nt 2390 C → T^†	—	—	—	2 (6%)	—	—	—	—
nt 2414 C → T	—	3 (11%)	2 (8%)	1 (3%)	1 (4%)	—	—	—
nt 2363 G → A plus nt 2414 C → T	—	16 (59%)	7 (27%)	10 (31%)	12 (43%)	—	—	—
nt 2363 G → A	15 (60%)	3 (11%)	6 (23%)	5 (16%)	—	10 (38%)	11 (44%)	—
Wild-type sequence	10 (40%)	5 (19%)	11 (42%)	14 (44%)	15 (53%)	16 (62%)	14 (56%)	28 (100%)

CN indicates congenital neutropenia; AML, acute myeloid leukemia; BMT, bone marrow transplantation; PB, peripheral blood; PMC, polymorphonuclear cell; MNC, mononuclear cell; nt, nucleotide position.

Before initiation of G-CSF therapy.

†

Nucleotide position refers to Fukunaga et al.5

View Large

This Feature Is Available To Subscribers Only